Why the study?
Is there an increased prevalence of cardiovascular disease and atherosclerosis in patients with systemic sclerosis?
Is there an increased prevalence of cardiovascular disease and atherosclerosis in patients with systemic sclerosis?
Answers are grounded in this paper and cite their sources.
This review highlights shared pathophysiological mechanisms between systemic sclerosis and atherosclerosis, suggesting an increased cardiovascular risk that requires confirmation in large cohort studies.
Microvascular disease is a prominent feature of systemic sclerosis (SSc) and leads to Raynaud's phenomenon, pulmonary arterial hypertension, and scleroderma renal crisis. The presence of macrovascular disease is less well established, and, in particular, it is not known whether the prevalence of coronary heart disease in SSc is increased. Furthermore, in terms of cardiac involvement in SSc, there remains conjecture about the relative contributions of atherosclerotic macrovascular disease and myocardial microvascular disease. In this review, we summarize the literature describing cardiovascular disease in SSc, discuss the pathophysiological mechanisms common to SSc and atherosclerosis, and review the surrogate markers of cardiovascular disease which have been examined in SSc. Proposed mediators of the vasculopathy of SSc which have also been implicated in atherosclerosis include endothelial dysfunction, a reduced number of circulating endothelial progenitor cells, and an increased number of microparticles. Excess cardiovascular risk in SSc is suggested by increased arterial stiffness and carotid intima thickening and reduced flow-mediated dilatation. Cohort studies of adequate size are required to resolve whether this translates into an increased incidence of cardiovascular events in patients with SSc.
No takes yet. Share an insight, caveat, or question.
Ngian et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: